

# Fingerprint your bioprocess for more robust production

Ales Strancar, August 2017

# About BIA Separations

- Incorporated in September 1998 in Ljubljana, Slovenia
- An OEM partnership with **Agilent** (former HP) in 2008
- In 2011 moved to **new dedicated facility** in Ajdovščina
- In 2012 strategic partnership with **SDK** Corporation (Shodex), 9B USD multinational company with HQ in Japan
- In 2016/2017 first projects to supply CIM product for biopharmaceutical drug manufacturing

# BIA Separations products and services

## Convective Interaction Media (CIM®)

### Pre-packed monolithic columns

CIMac™ Analytical and CIMmultus™/CIM® Preparative columns

## Services, Process development and Technical Support

Development of processes and methods for separation/concentration/purification of large biomolecules

Custom immobilisations, product development

## Process analytical technology

At-line PAT HPLC suite for improving process control and understanding



# Bioprocess Knowledge Packages

Based on 20 years of experience with over 500 bioprocess projects, BIA Separations is pleased to offer **Bioprocess Knowledge Packages** that include published/unpublished data, and experience-based, expert recommendations for purification and analytical methods that utilize our unique monolith chromatography columns and other best-in-class technologies to enable development of the most efficient and cost-effective bioprocess possible for your biomolecule.

(Please note: each purification strategy may vary based on the specific biomolecule, biologic drug specifications and upstream production methods. Bioprocess Knowledge Packages are made available to potential clients on a royalty-free basis)

# Bioprocess Knowledge Packages available

- **Bioprocess Knowledge Package-pDNA (works for > 30kbp)**
- **Bioprocess Knowledge Package-mcDNA**
- **Bioprocess Knowledge Package-RNA**
- **Bioprocess Knowledge Package-Adeno virus**
- **Bioprocess Knowledge Package-AAV (all serotypes)**
- **Bioprocess Knowledge Package-Flu virus (all serotypes)**
- **Bioprocess Knowledge Package-IVIG**
- **Bioprocess Knowledge Package-IgM**

# BIA Separations State-of-the-Art Production Facility > 30M USD investment




# Certifications & Approvals

- DMF for DEAE, QA and SO3 and C4 HLD CIM<sup>®</sup> monoliths were filed, others pending
- Partners audits (Baxter, Novartis, Octapharma, Boehringer Ingelheim, Teva, Agilent,.....)
- FDA audited (according to USA GMP regulations)
- JAZMP audited (according to EU GMP regulations)
- ISO 9001: 2008

## IP



- 4 US patents and their foreign equivalents granted, more pending:
  - CIM<sup>®</sup> technology and manufacturing
  - Different geometries including scale-up



# Convective Interaction Media (CIM<sup>®</sup>) monolithic columns



# Advantages of CIM<sup>®</sup> monolithic resins (membrane is „thin slice of the monolith“)




## Traditional approach - Porous particle:

- Diffusive mass transport – slow process or **lower resolution**
- Pores too small – very **low capacity**
- Counter current flow – shear forces – **lower yields**

## Novel approach – Monolithic columns:


- Convective mass transport – **flow independent resolution** and capacity – very fast processes
- Accessible surface for large molecules – **high capacity**
- Laminar flow - No shear forces – **better yields of e.g. IgM**

# Dimensions of CIM<sup>®</sup> radial monoliths




	1 mL	8 mL	80 mL	800 mL	8 L	40 L
I.D. (mm)	6.4	6.5	16.2	65	243	636
O.D. (mm)	18.3	14.4	33	105	285	680
Thickness (mm)	5.95	3.95	8.4	20	21	22

# Tubular format enables short monolithic column design at lab and industrial scale



# Introduction of composite materials to combine advantages of SS and plastics



- Epoxy thermoset composite
- Re-enforced with carbon fibers
- Coated pin-hole free with - USP Class VI Parylene C

- **Disposable but multiuse**
- **Stainless steel performance characteristics**
- **cGMP compliant**

**allows for robust continuous operations**

# CIMmultus™ composite materials – matching stainless steel characteristics


	1 mL		8 mL		80 mL		800 mL		8000 mL	
Type of column	CIM SS	CIMmultus™	CIM SS	CIMmultus™	CIM SS	CIMmultus™	CIM SS	CIMmultus™	CIM SS	CIMmultus™
Max pressure	18 bar	18 bar	20 bar	20 bar	20 bar	20 bar	7 bar	14 bar	7 bar	14 bar
Recommended flow rates (mL/min)	1-5	1-5	8-60	8-60	80-240	80-240	200-1300	200-1300	2000-10000	2000-10000
Max. flow rate (mL/min)	16	16	100	100	400	400	2000	2000	10000	10000
Max. operating temperature	40 °C	40 °C	40 °C	40 °C	40 °C	40 °C	40 °C	40 °C	40 °C	40 °C
L-t storage conditions	20% ethanol									
Sanitization for IEX, C4 HLD	1 M NaOH for at least an hour									

**BUT:**

- 3 times cheaper
- 5 times lighter
- allow for pre-packed column transport
- customer decides to use disposable column as single or multi use unit



# Main Applications – molecule type



# Binding capacities of CIM<sup>®</sup> columns

Molecules	Dynamic binding capacity
influenza	2 E+12 vp/mL
T7 phage	1 E+13 pfu/mL
M13 phage	4.5 E+13 pfu/mL
lambda phage	1 E+13 pfu/mL
PRD1 phage	6 E+13 pfu/ml
adenoviruses	2 E+12 vp/mL
baculovirus	2.4 E+11 pfu/ml
pDNA	8 mg/mL
genomic DNA	15 mg/mL
IgM	25 – 50 mg/mL
endotoxins	> 115 mg/mL

# Membrane versus CIM<sup>®</sup> monolith production of canine adenovirus Type 2 – yield doubled

Bioprocess development for canine adenovirus type 2 vectors

P Fernandes<sup>1,2</sup>, C Peixoto<sup>2</sup>, VM Santiago<sup>2</sup>, EJ Kremer<sup>3</sup>, AS Coroadinha<sup>1,2</sup> and PM Alves<sup>1,2</sup>

Step	Strategy	Recovery (%)
Clarification	Microfiltration	30
	<b>Centrifugation and microfiltration</b>	<b>90 ± 2<sup>a</sup></b>
Purification	Membrane adsorber	42 ± 5 <sup>a</sup>
	<b>Monolithic column</b>	<b>82 ± 2<sup>a</sup></b>
Polishing	Size exclusion chromatography	87 ± 6 <sup>a</sup>
	<b>Core bead prototype</b>	<b>86 ± 9<sup>a</sup></b>

Abbreviation:  $\Delta E1$ , E1-deleted. <sup>a</sup>Standard deviation of triplicate assays. The strategies in bold represent the best options to purify CAV-2 vectors.

*Fernandes, P et al, Bioprocess development for canine adenovirus type 2 vectors, Gene Therapy (2012), 1–8*



# Membrane versus CIM<sup>®</sup> monolith production of lentiviral vector - yield doubled

INFECTIOUS TITERS, CONCENTRATION FACTORS, AND RECOVERIES OBTAINED AT THE END OF EACH DOWNSTREAM PROCESS STEP, BEFORE AND AFTER OPTIMIZATION

	Before optimization			After optimization		
	Infectious titer ( $\times 10^7$ IP/ml)	CF	Recovery (%)	Infectious titer ( $\times 10^7$ IP/ml)	CF	Recovery (%)
Clarification						
Centrifugation	0.24 $\pm$ 0.01	–	71 $\pm$ 6			
Depth-filtration	0.25 $\pm$ 0.01	–	74 $\pm$ 5	0.30 $\pm$ 0.02	–	91 $\pm$ 6 <sup>a</sup>
Purification (AEXc)						
Sartobind D MA75	2.3 $\pm$ 0.1	12.5	28 $\pm$ 4			
CIM DEAE	6.1 $\pm$ 0.2	27.1	55 $\pm$ 2	8.0 $\pm$ 0.4	21.7	80 $\pm$ 5 <sup>b</sup>
Concentration (UF/DF)						
Vivaspin 100 KDa	4.50 $\pm$ 0.04	3.4	67 $\pm$ 6			
300 KDa	4.5 $\pm$ 0.2	1.1	68 $\pm$ 9			
Vivaflow 100 KDa	4.8 $\pm$ 0.1	1.6	72 $\pm$ 1			72 $\pm$ 1 <sup>c</sup>
Polishing (SEC)	0.11 $\pm$ 0.02	–	27 $\pm$ 2	0.82 $\pm$ 0.05	–	68 $\pm$ 7 <sup>d</sup>
Overall Recovery (%)		8				36 <sup>e</sup>

Results after optimization are shown for the methods presenting higher yields and chosen to be part of the downstream protocol developed herein due to their advantages.

<sup>a-d</sup>Recovery efficiency of total infectious particles, obtained after optimization of several conditions in each downstream processing (DSP) step: <sup>a</sup>increase of the flow rate from 50 to 100 ml min<sup>-1</sup>; <sup>b</sup>immediate five-fold dilution of viral preparations after elution; <sup>c</sup>no optimization was performed in this step due to the high recoveries obtained; <sup>d</sup>increase of the concentration of the loading material by six-fold; <sup>e</sup>overall recovery obtained after using the techniques that gave the best recoveries in each purification step. The errors correspond to standard deviation (n=3).

CF, concentration factor (in volume).

V. Bandeira et al., Downstream Processing of Lentiviral Vectors: Releasing Bottlenecks, Human Gene Therapy Methods 23:1-9 (August 2012)



# Evaluation of different supports for purification of live influenza A - yield doubled

Average values	QA monolith	Q membrane	Q porous particles	semi-affinity porous particles
Virus Recovery	54%	35%	35%	27%
DNA Depletion	96%	95%	95%	91%
Protein Depletion	95%	94%	98%	99%
Dynamic Binding Capacity	10.3 log <sub>10</sub> TCID50/mL Support	10.3 log <sub>10</sub> TCID50/mL Support	9.0 log <sub>10</sub> TCID50/mL Support	8.4 log <sub>10</sub> TCID50/mL Support

*Maurer et al., Purification of Biological Products, Waltham, MA/USA, 2007*

**50% better recovery results in e.g. 1,5 M doses of vaccine instead of 1 M doses, at the same costs of the process = 0,5 M doses are pure profit**

# Plasmid DNA purification using CIM<sup>®</sup> DEAE columns: 15-fold increase in productivity



CIM<sup>®</sup> DEAE binding capacity  
= ~8 mg/ml

Used for CP III trials

## Boehringer Ingelheim: „15-fold increase in productivity“

- High binding capacity at relevant flow rates
- High elution concentration - pDNA eluted in lower volume (important for SEC!)
- Fast process (no product loss due to oxidative degradation or enzymatic attack)

# Economic benefit for the customer using CIM<sup>®</sup> Monolith Plasmid DNA purification pack

## 1 ml CIM monolith – BIA Sep

### Calculations

Buffer	76,3 ml buffer/mg pDNA
Time	23,6 min /mg pDNA
Recovery	85%

### Costs using column for 1 run

Quantity of purified pDNA	5,10 mg PDNA
€ (Column costs)	114 €/mg pDNA
€ (Column + buffer)	114 €/mg pDNA

### Costs using columns for 10 runs

Quantity of purified pDNA	51 mg pDNA
€ (Column costs)	11,4 €/mg pDNA
€ (Column + buffer)	11,8 €/mg pDNA

### Costs using columns for 20 runs

Quantity of purified pDNA	102 mg pDNA
€ (Column costs)	5,7 €/mg pDNA
€ (Column + buffer)	6,1 €/mg pDNA
€ (column + buffer+ work)	15,4 €/mg pDNA

CIM  
monolithic  
columns offer  
**3 times  
cheaper**  
purification  
costs of pDNA  
for gene  
therapy

## Particle based

### Calculations

Buffer	108,0 ml buffer/mg pDNA
Time	70,0 min /mg pDNA
Recovery	79%

### Costs using column for 1 run

Quantity of purified pDNA	4 mg PDNA
€ (Column costs)	227 €/mg pDNA
€ (Column + buffer)	228 €/mg pDNA


### Costs using columns for 10 runs

Quantity of purified pDNA	40 mg pDNA
€ (Column costs)	23 €/mg pDNA
€ (Column + buffer)	24 €/mg pDNA

### Costs using columns for 20 runs

Quantity of purified pDNA	79 mg pDNA
€ (Column costs)	11 €/mg pDNA
€ (Column + buffer)	12 €/mg pDNA
€ (column + buffer+ work)	42 €/mg pDNA

# Separations of empty, full and damaged AAV capsids using Anion exchange CIMmultus™ QA column





# Is full AAV particle only one species?

## Check with pH gradient - unmatched resolution


Column: CIMac™ SO3

Mf A: 20 mM acetate, pH 4

Mf B: 20 mM HEPES + 1M NaCl, pH 8



# Separation of exosomes using CIM<sup>®</sup> large channel anion exchange column – enabling feature






**PATfix™**

**In-process control HPLC  
system with unique  
software**




# What is Process Analytical Technology (PAT)?

Process Analytical Technology is „a system for designing, analyzing, and controlling manufacturing processes through timely measurements of critical quality and performance attributes of raw and in-process materials and processes, with the goal of ensuring final product quality.“ (FDA PAT Guidance, 2004)




# Proper process understanding and good process control = Robust process

Provides an opportunity to apply a control closer to the source of variability in the process



# Reality in bioprocessing



# BIA Separations PATfix™



**Integrated system used to detect changes and quantify complex analytes**

**Custom tailored to meet requirements of bioanalytical HPLC techniques**

# BIA Separations PATfix™




inCygnt  
for chromatography

- Easy to use data management
- Mass visualization of chromatograms
- Automatic detection of changes
- Prediction of complex CQAs
- Column without carry-over
- Immediate sample analysis

# Use of the HPLC is mandatory for accurate mass balance calculation



CIMac™ / Bio-monolith™ HPLC Columns



$10 \text{ ml/min} = 4500 \text{ cm/h} = 360 \text{ CV/min}$  (res. time: 0,1 s) = faster than biosensor

**No entrapment in the column, no carry-over**

# Advantages of CIM<sup>®</sup> monolithic resins – No entrapment in the column, no carry-over



# CIMac™ analytical columns for PAT HPLC – no carry over of large molecules or viral particles



Available:



- CIMac™ QA
- CIMac™ DEAE
- CIMac™ SO3
- CIMac™ EDA
- CIMac™ pDNA
- CIMac™ Adeno
- CIMac™ AAV empty/full

Soon to come:

- CIMac™ AAV total
- CIMac™ Lenti
- CIMac™ Vaccinia



# CIMac™ AAV empty/full columns; Intra-batch reproducibility (Batch 15-003-AV01)




Retention time difference of full and empty AAV capsids, both UV and FLD.

**UV: RSD of  $\Delta t_{ret}(full - empty)$ : 6 %; FLD: RSD of  $\Delta t_{ret}(full - empty)$ : 4 %**

**AAV is sticking to all plastics – sample preparation is the key step for accurate results**


# BIA Separations PATfix™ workflow



# PATfix™ Optimal point of harvest

Unit operation is a highly dynamic system.


Case: mAb production



## What is inside?


- IgG,
- Nucleic acids,
- Host cell protein,
- Media components,
- CHO cells,
- Product agglomerates, ...

## How it is evolving?




# Determination of optimal time-point of harvest (Pichia Pastoris, protein expression)

- Samples taken at regular intervals, centrifuged, buffer adjusted and injected directly onto the column.




# Determination of optimal time-point of harvest (*Pichia Pastoris*, protein expression)

- Chromatogram alignment to increase the accuracy of prediction




# Determination of optimal time-point of harvest (*Pichia Pastoris*, protein expression)


Deviation analysis



# Intravenous immunoglobulin (IVIg) purification process scheme



# IVIg purification – first chromatography step using strong AEX CIMmultus column



Column: 8 mL CIMmultus QA

Loading buffer: 20 mM Na-acetate, pH 5.0

Elution: loading buffer + 1 M NaCl

CIP: 1 M NaOH + 2 M NaCl


Sample: 1g Cohn II+III paste in 10 mL loading buffer

Product IGIV in flow through fraction(s)




# HPLC fingerprint using strong AEX CIMac column in linear gradient


## CIMac AEX fingerprint chromatogram - sample



## Preparative chromatogram




## SEC chromatogram - sample




# HPLC fingerprint using strong AEX CIMac column in linear gradient


## CIMac AEX fingerprint chromatogram – FT fract. 1



## Preparative chromatogram




## SEC chromatogram – FT fract. 1




# HPLC fingerprint using strong AEX CIMac column in linear gradient


## CIMac AEX fingerprint chromatogram – FT fract. 2



## Preparative chromatogram




## SEC chromatogram – FT fract. 2




# HPLC fingerprint using strong AEX CIMac column in linear gradient


## CIMac AEX fingerprint chromatogram – FT fract. 3



## Preparative chromatogram




## SEC chromatogram – FT fract. 3




# HPLC fingerprint using strong AEX CIMac column in linear gradient


## CIMac AEX fingerprint chromatogram – FT fract. 4



## Preparative chromatogram




## SEC chromatogram – FT fract. 4




# HPLC fingerprint using strong AEX CIMac column in linear gradient


## CIMac AEX fingerprint chromatogram – FT fract. 5



## Preparative chromatogram




## SEC chromatogram – FT fract. 5




# HPLC fingerprint using strong AEX CIMac column in linear gradient


## CIMac AEX fingerprint chromatogram – Elution fract.




## Preparative chromatogram



## SEC chromatogram – Elution fract.



# PATfix™ Fingerprint approach to study robustness of the AAV fermentation scale-up



Average relative standard deviation of all area normalized fingerprints is 5.6 % (including the sample obtained with fermentation at different scales (50 L vs 200 L)).  
One can conclude the fermentation is very robust.



# PATfix™ cheaper info as traditional methods

**PATfix fingerprint injection = about 20 € (column + buffers + labor), takes about 20 min**

(crio)TEM: 125 €, 30 min

AUC: 200 €, 1 h

SDS-PAGE: 20 €, 4 h

Infectivity: < 10 €, 3-7 days


ELISA: 5 € / well, 4 h

SDS-PAGE: 20 €, 4 h

qPCR: 20 € / well, 3-4 h

ssPCR: 30 € /well, 3-4 h

AGE: 20 €, 2 h



**To SUM up:**

**Traditional methods per sample: 100 - 400 €**



**Time: 1 day to 1 week**

**PATfix per sample: 20 €**

**Time: 20 min**

**BUT not magic box – needs work to understand**

# Adenovirus purification process monitoring using fingerprint approach



## Fingerprinting

Column: CIMac™ Adeno

Flow rate: 1 mL/min

Buffer A: 50 mM Tris, pH 8.0

Buffer B: 50 mM Tris + 1M NaCl, pH 8.0


# CIMac™ pDNA Analytical Column

Product number	Product name	Description
150.8501-1.4	CIMac pDNA column	DEAE monolithic matrix with a controlled ligand density and structural characteristics


- DEAE monolithic matrix with a controlled ligand density and structural characteristics
  - 5.2 mm ID x 15 mm L, V = 0.32 mL
- Flow rates: 0.2 – 2 mL/min
- Maximum pressure over the column: 100 bar



# Optimization of precipitation with CaCl<sub>2</sub>



## CIMmultus DEAE preparative column:



## PAT HPLC to balance between RNA removal and pDNA yield

# CIMac™ pDNA Analytical Column – alkaline lysis optimisation










Figure 1: Agarose gel electrophoresis - Molecular weight marker (lane M), sample alkaline lysate plasmid pEGFP-N1 (lane A), peak 1 (lane 1), peak 2 (lane 2), peak 3 (lane 3), peak 4 (lane 4), peak 5 (lane 5), pDNA open circular form standard (lane 6)

# CIMac™ pDNA Analytical Column – 1st chromatography step



Conditions: Flow rate – 1 ml/min; Buffer A – 200 mM Tris pH 8.0 and buffer B – 200 mM TRIS + 1 M NaCl pH 8.0; Injection volume – 20 µl; Sample was diluted 1:3 with water; UV detection – 260 nm; Peak 1 and Peak 2 – other impurities, Peak 3 – RNA, Peak 4 – OC pDNA, Peak 5 – SC pDNA.


# CIMac™ pDNA Analytical Column – 2nd chromatography step



Conditions: Flow rate – 1 ml/min; Buffer A – 200 mM Tris pH 8.0 and buffer B – 200 mM TRIS + 1 M NaCl pH 8.0; Injection volume – 5 µl; UV detection – 260 nm; Peak 1 – OC pDNA form; Peak 2 – SC pDNA form;

Topoisomers	
OC	2 %
SC	98 %

# Online nuclease treatment monitoring




- HS Nuclease (MoBiTec; Cat No 1070-01; Lot # 202222; 250 units/ $\mu\text{L}$ ) diluted with Chromatography Buffer A to 1 unit/ $\mu\text{L}$ , 1.5 units/ $\mu\text{L}$  and 2 units/ $\mu\text{L}$ .
- Final Nuclease concentrations: 50 units/mL; 100 units/mL; 150 units/mL.
- Aliquots incubated in water bath at 37°C; every 30 minutes one aliquot drawn and immediately analyzed by HPLC.

Loop volume: 1 mL, injected 1 mL of 3 times diluted samples; flow rate: 1mL/min.



# Online nuclease treatment monitoring – cost comparison PATfix™ – traditional methods



qPCR: 20 € / well, 3-4 h

ssPCR: 30 € /well, 3-4 h

AGE: no numeric result

Total labor: 1000 €

**Total: up to 3000 € for 3 reactions**

PATfix:

Prep labor: 100 € & go home

CIMac run: 2 - 5 €


**Total: 250 € for 3 reactions**

# Conclusions

- HPLC fingerprinting is convenient technique to measure multiple sample parameters simultaneously:
  - + Reproducible
  - + High resolution
  - + Flexible
  - + Fast but not yet on-line
  - **Difficult to evaluate (needs experience)**
- PATfix™ algorithms
  - + System verification
  - + Sample stability control
  - + Dilution control
  - + Advanced mathematical manipulation of chromatograms
  - + **Fast, reliable and simultaneous prediction of multiple sample components**

# BIA Separations - industry standard for production of Gene Therapy products and Exosomes

- Platform processes for pDNA, AAV, Flu and Adeno, ....
- First drug purified using CIM<sup>®</sup> monoliths on the market , one passed CPIII trial (pDNA for gene therapy), 5 projects in CPIII.
- More than 100 projects in CPI – CPII trials (various Influenza, various Adenovirus, various AAV, bacteriophages, various IgMs, Inter-alpha-inhibitors,...).
- More than 500 projects in pre-clinical trials (Influenza A and B virus (eggs, Vero and MDCK cells), Rabies virus, Rotavirus, AAV, various Adenovirus subtypes, Hepatitis A, Vaccinia, Muly, MVM, Feline calicivirus, Japanese encephalitis, Crimean-Congo hemorrhagic fever, Hantaan virus, VLP (Hepatitis B, HPV, Influenza, Adenovirus), bacteriophages (Lambda, T4, VDX10, Pseudomonas phage), Tomato and Pepino Mosaic virus, pDNA, IgM, various proteins).



For any additional information please contact us:

**[sales@biaseparations.com](mailto:sales@biaseparations.com)**

Tel.: +386 5 9699 500

**[orders@monoliths.com](mailto:orders@monoliths.com)**

Fax.: +386 5 9699 599

**[tech-support@monoliths.com](mailto:tech-support@monoliths.com)**

**[www.biaseparation.com](http://www.biaseparation.com)**

